Loading
German breast oncologist whose ADAPT trials use biology to decide who can have less chemotherapy.
Nadia Harbeck leads the West German Study Group ADAPT programme, which uses genomic assays and early response to tailor neoadjuvant and adjuvant therapy, and chaired the 2019 Nature Reviews Disease Primer on breast cancer. She is a co-author of the St Gallen consensus and of monarchE, and directs one of Europe's largest breast centres. Her focus is biology-driven de-escalation of chemotherapy.
| Title | Journal | Year |
|---|---|---|
| Breast cancer | Nature Reviews Disease Primers | 2019 |
| De-escalation strategies in HER2-positive early breast cancer (WSG-ADAPT HER2+/HR-) | Annals of Oncology | 2017 |
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags breast, de-escalation.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags breast, de-escalation.
Shares HR-positive / HER2-negative breast cancer and the tags breast, de-escalation.
Shares HER2-positive breast cancer and the tags breast, de-escalation.
Shares HR-positive / HER2-negative breast cancer and the tags breast, de-escalation.
Shares HR-positive / HER2-negative breast cancer and the tags breast, de-escalation.
Shares HR-positive / HER2-negative breast cancer and the tags breast, de-escalation.
Shares monarchE, HR-positive / HER2-negative breast cancer and the tag breast.